Summary of Key Points from the Conference Call Industry Overview - The conference call primarily discusses the **pharmaceutical industry** and its performance in the context of the upcoming Spring Festival and the Two Sessions in China. The focus is on the investment opportunities within the pharmaceutical sector, particularly in innovative drugs and services [1][2][3]. Core Insights and Arguments - **Market Performance**: Historically, small-cap stocks such as the CSI 500, CSI 1000, and National 2000 have shown a strong performance with a 90% excess win rate and a median excess return of approximately 3% from the New Year to the pre-Spring Festival period [1][2]. - **Consumer Sector**: The consumer sector has performed well with a 60% win rate in Q1, particularly peaking at 67% in March, making it the top performer among major styles [2]. - **Pharmaceutical Sector**: Despite recent adjustments, the pharmaceutical sector had a notable performance in February with a 73% excess win rate and a median excess return of 1.1%, ranking it among the top ten in the Shenwan primary industry [1][2]. - **Investment Opportunities**: During the Spring Rally, segments such as innovative drugs, medical devices, and traditional Chinese medicine are highlighted as key areas for investment due to their growth potential and strong domestic demand [1][5][6]. Additional Important Insights - **Long-term Outlook**: By 2026, the pharmaceutical innovation sector is expected to benefit from an engineer dividend, enhancing research efficiency, cost, and speed. The innovative drug market is seen as entering a long-term growth phase, with projections indicating that by 2030, the revenue and profit share from pharmaceutical innovation could rise significantly [2][7]. - **CRO and Life Sciences**: Since 2025, there has been a recovery in demand for Contract Research Organizations (CRO) and upstream life sciences, with a strong rebound anticipated in 2026, particularly in preclinical CROs [8][9]. - **Traditional Chinese Medicine**: The traditional Chinese medicine sector is expected to recover normal growth by 2026, supported by policy changes and decreasing raw material costs, which will enhance profit growth [10]. - **AI in Healthcare**: The potential for AI in healthcare is significant, with applications in diagnostics and drug discovery. The need for milestone events to catalyze this sector's growth is emphasized [17][20]. Conclusion - The pharmaceutical industry is positioned for growth, with various segments offering unique investment opportunities. The overall sentiment is optimistic, particularly regarding innovative drugs and the recovery of traditional medicine, supported by favorable market conditions and policy changes.

Core Viewpoint - The strategic cooperation agreement between China Digital Technology (01796) and Xinhua Pharmaceutical Development (Qianjiang) aims to explore collaboration opportunities in traditional Chinese medicine and the health industry in China [1] Group 1: Strategic Cooperation - The agreement focuses on resource development, production, supply chain, modern product research and development, marketing, and capital market collaboration in the traditional Chinese medicine sector [1] - The goal of the strategic cooperation is to achieve resource complementarity and synergistic development between the two companies [1] Group 2: Technological Integration - Both parties intend to leverage big data and advanced intelligent computing to drive the standardization, modernization, and marketing of traditional Chinese medicine through artificial intelligence [1] Group 3: Management and Progress - The companies will hold senior management meetings periodically to discuss the forms, directions, and other related matters of the cooperation projects based on market conditions and collaboration progress [1]

Core Viewpoint - The strategic cooperation agreement between China Digital Technology (01796) and Xinhua Pharmaceutical Development (Qianjiang) aims to explore collaboration opportunities in traditional Chinese medicine and the health industry in China [1] Group 1: Strategic Cooperation - The agreement focuses on resource development, production, supply chain, modern product research and development, marketing, and capital market collaboration in the traditional Chinese medicine sector [1] - The goal of the strategic cooperation is to achieve resource complementarity and synergistic development [1] Group 2: Technological Integration - Both parties intend to leverage big data and advanced intelligent computing to drive the standardization, modernization, and marketing of traditional Chinese medicine through artificial intelligence [1] Group 3: Management Engagement - The companies will hold senior management meetings periodically to discuss the forms, directions, and other related matters of the cooperation projects based on market conditions and progress [1]

Core Insights - The collaboration between Shaanxi and Jiangsu provinces has strengthened significantly, focusing on various industries and projects, particularly in the context of the "14th Five-Year Plan" and the upcoming "15th Five-Year Plan" [1][3] Group 1: Collaboration Achievements - Over the past five years, the collaboration has led to the establishment of 916 enterprises in Shaanxi, with actual investments exceeding 477 billion yuan, covering over 20 provincial key industrial chains [1] - Various industrial cooperation projects have been successfully implemented, including those in plush toys, traditional Chinese medicine, dairy goats, and automotive parts [1] - A total of 68 industrial parks have been co-built under the collaboration framework, achieving full coverage of "one county, one park" [1] Group 2: Economic Development and Support - The collaboration has injected momentum into the economic development of Han Zhong, with projects in textiles, traditional Chinese medicine, and modern materials being implemented [2] - Shaanxi has invested 19 billion yuan this year to support key county-level industries, enhancing the development of co-built industrial parks [2] Group 3: Focus on Innovation and Technology - Future cooperation will emphasize technology innovation and industrial transformation, with a keen interest in Jiangsu's mechanisms and experiences in these areas [3][5] - Jiangsu's industrial technology research institute serves as a model for Shaanxi, showcasing effective mechanisms for technology transfer and innovation [5][6] - The collaboration aims to enhance agricultural technology transfer and establish a diversified agricultural technology promotion service model [6] Group 4: Strategic Goals and Future Directions - The two provinces plan to deepen cooperation in high-level openness and integration of scientific and technological industries, with a focus on international trade channels and overseas industrial parks [7] - There is an expectation to create high-level innovation platforms and enhance industrial chain collaboration under the "15th Five-Year Plan" [7]

会上，由广州医科大学附属第一医院、广州呼吸健康研究院、呼吸疾病全国重点实验室、天津中医药大 学中医药研究院、现代中医药海河实验室联合发起的"2026中医药呼吸健康发展共同体"正式启动。步长 制药（603858）继2025年荣列"中医药呼吸健康发展共同体"首批成员单位之后，再获授牌。该共同体将 聚焦呼吸疾病"预防-筛查-诊断-治疗-康复"全周期管理，重点开展循证医学研究、适宜技术推广、人才 联合培养等工作，致力于将个体化临床经验转化为标准化诊疗路径，为完善全国呼吸疾病防治网络提供 有力支撑。 中证报中证网讯(王珞)12月5-6日，以"中西医协同产学研创新：共筑呼吸健康新格局"为主题的第二届中 国呼吸健康大会在广州启幕，发布《强化中西医结合防治慢性阻塞性肺疾病专家共识》等多项成果。大 会由中国工程院院士钟南山、张伯礼共同担任大会主席，汇聚了近2000名呼吸病学、中医药学等领域的 产学研代表，以"学术交流+成果展示"双线并行的形式，不仅有前沿学术论坛供专家学者分享研究进 展，同时设置了呼吸系统领域医药创新成果展区，产学研深度融合全方位探索呼吸系统疾病"筛、防、 诊、治、康"的创新路径，为健康中国建设注入新动能。 ...

12月9日，省工商联与澳门工商联会合作交流对接会在哈尔滨召开。省工商联党组成员、副主席乔惠东主持会议并讲话。澳门工商联会执行会长吴华威出 席会议。 吴华威表示，澳门工商联会将进一步加强与黑龙江省经贸交流交往，拟组织澳门中小企业参加第三十五届哈洽会，在生物医药、中医药、绿色食品、文化 旅游等领域积极开展务实合作。 会上，澳门工商联会中医药大健康委员会副主任、澳门青创国际集团有限公司副总裁和学斌作"澳门中医药大健康出海服务中心"专题推介。省工商联健康 产业商会、省医疗器械行业协会、玉生堂慧中医科技有限公司等我省10余家商协会和民营企业与澳门工商联会、吴淦记集团、澳门青创国际集团、澳门通 股份有限公司等进行深入对接交流。省工商联与澳门工商联会签订友好商会协议，省工商联健康产业商会与澳门工商联会签订战略合作协议。 12月9日，省工商联与澳门工商联会合作交流对接会在哈尔滨召开。省工商联党组成员、副主席乔惠东主持会议并讲话。澳门工商联会执行会长吴华威出 席会议。 吴华威表示，澳门工商联会将进一步加强与黑龙江省经贸交流交往，拟组织澳门中小企业参加第三十五届哈洽会，在生物医药、中医药、绿色食品、文化 旅游等领域积极开展务实合 ...

Core Insights - The conference held by Gushengtang on December 5, 2025, showcased significant collaborations and achievements in the integration of traditional Chinese medicine (TCM) and artificial intelligence (AI), highlighting the company's commitment to modernizing TCM and expanding its international presence [1][3]. Group 1: AI Model Development - Gushengtang announced partnerships with four leading research teams to develop a TCM AI model, enhancing clinical applicability and reliability through interdisciplinary collaboration [7][8]. - The collaboration aims to create a robust AI evaluation system and develop AI applications like the "National Medicine AI Avatar" to assist in diagnosis and patient management [8][9]. Group 2: Clinical Research Integration - A clinical research integration platform was launched to accelerate the transformation of clinical research outcomes, focusing on real-world data evaluation in TCM [10]. - Gushengtang has completed 16 internal formulations, with one product successfully certified and launched in Singapore, demonstrating its strong R&D capabilities [10]. Group 3: Global Expansion and Ecosystem Development - Gushengtang is expanding its service boundaries through a strategic partnership with Amap, integrating TCM services with navigation and local life scenarios to enhance user accessibility [11]. - The company is adopting a "merger + cooperation + self-built" strategy for global expansion, with a full acquisition of Singapore Chinese Medicine to increase its presence in the region [12].

Core Insights - The conference held by Guoshengtang on December 5, 2025, showcased significant collaborations and innovations in the integration of traditional Chinese medicine (TCM) and artificial intelligence (AI) [1][3] - Guoshengtang aims to modernize and internationalize TCM, responding to national policy initiatives and expanding its service capabilities through AI and overseas market development [3] Group 1: Collaborations and Innovations - Guoshengtang announced partnerships with four leading research teams to develop a TCM AI model, enhancing clinical applicability and reliability [6] - The company launched the "National Medicine AI Avatar" product, providing real-time clinical decision support for young doctors, currently in trial operation across several specialties [7] - A clinical research integration platform was initiated to address real-world data evaluation challenges in TCM, with 16 internal formulations already registered [8] Group 2: Global Expansion and Market Strategy - Guoshengtang signed a strategic cooperation agreement with Amap to integrate TCM services with navigation and local life scenarios, enhancing user accessibility [10] - The company is pursuing a "merger + cooperation + self-built" strategy for global expansion, with a full acquisition of Singapore Chinese Medicine to increase its presence in the region [10] - The overall strategy emphasizes AI-driven diagnosis, research-driven products, and a comprehensive flow ecosystem to support TCM's international outreach [10]

Core Viewpoint - The unique advantages of traditional Chinese medicine (TCM) in the prevention and treatment of influenza are increasingly recognized, but public misconceptions can lead to ineffective prevention and delayed treatment, ultimately harming health [1]. Group 1: Misconceptions about TCM - Misconception 1: TCM has no toxic side effects, so it can be consumed in excess without concern. In reality, TCM emphasizes "medicinal properties," and excessive consumption can harm the spleen and stomach, especially for certain herbs [3]. - Misconception 2: Patients often stop taking TCM once symptoms improve, which can lead to a relapse of the illness. In Beijing, the flu is characterized by complex symptoms, and premature cessation of treatment may allow the illness to return [4]. - Misconception 3: TCM can replace Western medicine, and patients avoid antipyretics during high fever. TCM is effective in symptom relief but should be used alongside Western medicine for severe symptoms or complications [5]. - Misconception 4: Pediatric massage and scraping can be done indiscriminately, with more marks indicating better results. Incorrect techniques can harm children's delicate skin, and proper methods should be learned [6]. - Misconception 5: After a fever subsides, patients excessively rely on tonics like ginseng and cordyceps, which can hinder the elimination of the virus and worsen symptoms. A light diet is recommended during recovery [7].

Core Viewpoint - The article highlights the significance of traditional Chinese medicine (TCM) in Taiwan, emphasizing its historical roots, current applications, and cultural integration within Taiwanese society [1][2]. Group 1: Historical Context - TCM has been present in Taiwan since 1652, when the first recorded TCM practitioner, Shen Guangwen, settled in Taiwan after being blown off course by a typhoon [2]. - The influx of Han Chinese immigrants from Fujian and Guangdong provinces further established TCM practices in Taiwan, leading to its integration into daily life [2]. Group 2: Current Landscape - Taiwan currently has over 4,000 TCM clinics and approximately 8,000 TCM practitioners, indicating a robust presence of TCM in the healthcare system [2]. - The popularity of TCM has diversified, with TCM beauty treatments gaining traction among the public, as evidenced by the recent "Medicine Beauty" exhibition at the Li Fu TCM Museum [2]. Group 3: Cultural Significance - The Li Fu TCM Museum showcases a rich collection of TCM artifacts, including ancient texts and medicinal materials, reflecting the deep-rooted cultural heritage of TCM [1][3]. - The exhibition features ancient beauty recipes attributed to historical figures like Wu Zetian and Yang Guifei, demonstrating the enduring appeal of TCM beauty practices among younger generations in Taiwan [3].